Soleus Capital Management, L.P. Inhibrx, Inc. Transaction History

Soleus Capital Management, L.P.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $8.28 Million - $10 Million	252,871 Added 1685.81%	267,871 $9.36 Million
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $7.75 Million - $20.3 Million	-534,183 Reduced 97.27%	15,000 $570,000
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $1.2 Million - $2 Million	76,000 Added 16.06%	549,183 $10.1 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $596,669 - $978,735	35,181 Added 8.03%	473,183 $12.3 Million
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $743,535 - $1.09 Million	-40,300 Reduced 8.43%	438,002 $8.27 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $2.31 Million - $3.81 Million	114,400 Added 31.44%	478,302 $11.8 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $4.21 Million - $9 Million	363,902 New	363,902 $6.53 Million
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $2.62 Million - $4.51 Million	-97,979 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$25.18 - $37.81 $3.65 Million - $5.48 Million	-144,810 Reduced 59.64%	97,979 $3.26 Million
Q2 2021 Aug 16, 2021	SELL	$14.69 - $27.52 $2.33 Million - $4.37 Million	-158,704 Reduced 39.53%	242,789 $6.68 Million
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $3.05 Million - $7.74 Million	187,686 Added 87.78%	401,493 $8.06 Million
Q4 2020 Feb 16, 2021	SELL	$15.96 - $50.0 $3.08 Million - $9.63 Million	-192,693 Reduced 47.4%	213,807 $7.05 Million
Q3 2020 Nov 13, 2020	BUY	$16.77 - $20.65 $6.82 Million - $8.39 Million	406,500 New	406,500 $7.32 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $550M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.